Inclusion Criteria:

- Histologically confirmed SCLC who presented with Limited Stage (LS) at diagnosis.

- Measurable disease at the time of initial therapy

- Appropriate treatment for LS-SCLC including radiotherapy and chemotherapy.

- Responsive disease to standard chemoradiation therapy as defined by RECIST

- Patients with CR after chemoradiation therapy are strongly recommended to be treated
with prophylactic cranial irradiation

- CBC with an absolute neutrophil count (ANC) >/= 1,000/uL, hemoglobin >/= 8.0 g/DL
and platelet count >/= 75,000/uL.

- Normal prothrombin time (PT) and partial thromboplastin time (aPTT), unless on
monitored anticoagulation therapy for medical conditions not excluded in the trial.

- Liver enzymes: total bilirubin less than or equal to 2mg/dL; AST and ALT less than
1.5X the upper limit of normal.

- Creatinine clearance of >/= 60 mL/min

- Pulmonary: DLCO greater than 50%

- Cardiac: left ventricular ejection fraction greater than 45%

Exclusion Criteria:

- Patient with stable (SD) or progressive disease (PD) after 4 cycles of standard
cisplatin and etoposide and concurrent chest irradiation

- Pregnant or lactating woman

- HIV infection confirmed by NAT

- Common variable immunodeficiency

- Active CNS malignancy

- Active bacterial, fungal or viral infection

- Unfavorable psychosocial evaluation or history of poor compliance to prescribed
medical care

- Prior history of autologous or allogeneic hematopoietic cell transplantation

- Presence of protocol specific comorbid conditions